Search

Laboratorios Farmaceuticos Rovi SA

Fechado

SetorSaúde

60.1 -0.33

Visão Geral

Variação de preço das ações

24h

Atual

Mín

59.9

Máximo

60.15

Indicadores-chave

By Trading Economics

Rendimento

3.9M

27M

Vendas

4.8M

160M

P/E

Médio do Setor

22.664

36.442

EPS

0.423

Rendimento de Dividendos

1.64

Margem de lucro

16.767

Funcionários

2,188

EBITDA

4.2M

35M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+34.86% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.64%

3.00%

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

181M

3B

Abertura anterior

60.43

Fecho anterior

60.1

Sentimento de Notícias

By Acuity

50%

50%

148 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de out. de 2025, 18:13 UTC

Grandes Movimentos do Mercado

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 de out. de 2025, 17:05 UTC

Grandes Movimentos do Mercado

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

18 de out. de 2025, 13:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 de out. de 2025, 13:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 de out. de 2025, 13:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 de out. de 2025, 13:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 de out. de 2025, 08:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

18 de out. de 2025, 07:00 UTC

Ganhos

A Growing Nimby Movement Could Upend the Data Center Boom -- Barrons.com

17 de out. de 2025, 23:25 UTC

Aquisições, Fusões, Aquisições de Empresas

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 de out. de 2025, 22:15 UTC

Conversa de Mercado

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 de out. de 2025, 21:15 UTC

Conversa de Mercado

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 de out. de 2025, 21:07 UTC

Conversa de Mercado

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 de out. de 2025, 21:07 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

17 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de out. de 2025, 20:34 UTC

Conversa de Mercado

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 de out. de 2025, 20:27 UTC

Conversa de Mercado

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 de out. de 2025, 19:46 UTC

Conversa de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 de out. de 2025, 19:45 UTC

Conversa de Mercado

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 de out. de 2025, 18:45 UTC

Conversa de Mercado

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 de out. de 2025, 17:51 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de out. de 2025, 17:51 UTC

Conversa de Mercado

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 de out. de 2025, 17:44 UTC

Conversa de Mercado

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 de out. de 2025, 17:35 UTC

Conversa de Mercado

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 de out. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

17 de out. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de out. de 2025, 16:14 UTC

Conversa de Mercado

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 de out. de 2025, 16:04 UTC

Conversa de Mercado

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 de out. de 2025, 15:58 UTC

Conversa de Mercado

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 de out. de 2025, 15:56 UTC

Ganhos

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 de out. de 2025, 15:43 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

34.86% parte superior

Previsão para 12 meses

Média 80.85 EUR  34.86%

Máximo 90 EUR

Mínimo 71.7 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

148 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat